Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
View Patent ↗The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.
1. An isolated monoclonal antibody that binds to ERG, wherein the antibody binds to an epitope located within amino acids 278-363 of the polypeptide encoded by a nucleic acid comprising the sequence of SEQ ID NO: 1.
2. The isolated monoclonal antibody of claim 1 , wherein the antibody binds to ERG1, ERG2, and ERG3 polypeptides.
3. The isolated monoclonal antibody of claim 2 , wherein the ERG1, ERG2, and ERG3 polypeptides are human polypeptides.
4. The isolated monoclonal antibody of claim 2 , wherein the antibody has an affinity constant (Ka) of at least 10 8 M −1 for binding ERG1, ERG2, and ERG3 polypeptides.
5. The isolated monoclonal antibody of claim 1 , wherein the antibody specifically binds ERG1, ERG2 and ERG3 polypeptides, but does not specifically bind to another protein of the ETS family.
6. The isolated monoclonal antibody of claim 1 , wherein the antibody binds to ERG in a biological sample under suitable conditions.
7. The isolated monoclonal antibody of claim 6 , wherein the biological sample comprises a prostate cancer cell.
8. The isolated monoclonal antibody of claim 3 , wherein the antibody specifically binds ERG1, ERG2 and ERG3 polypeptides, but does not specifically bind to another protein of the ETS family.